The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Open accessAbstract
SUMMARY While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole genome and transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor / 38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kilobases upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most PCas express AR throughout the course of the disease2–5”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, deep deletions (primarily of BRCA2; Supplementary Fig. 23) occurred much more frequently in prostate cancer (33%) compared to other cancer types, consistent with previous observations28.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · cited 1×
“While over 160,000 American men are diagnosed with prostate cancer each year, <20% of patients will experience progression to the lethal form of the disease, termed metastatic castration-resistant prostate cancer (mCRPC) (Siegel et al., 2018).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724 · cited 2×
“2.0 Zhang et al., 2013 https://cran.r-project.org/web/packages/RCircos/index.html ANNOVAR v2018Apr16 Wang et al., 2010 http://annovar.openbioinformatics.org/en/latest/ Cell 174, 1–12.e1–e3, July 26, 2018 e1 Please cite this article in press as: Quigley et al., Genomic Hallmarks and Structural…”
InfluentialCingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Ohno, S. (1970) · doi:10.1007/978-3-642-86659-3 · Cited by 7,833
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 3×
“We observed mutually exclusive fusions activating the ETS family members ERG, ETV1, ETV4, and ETV5 in 59% of our cohort (Figure 1C; fusions listed in Table S3).”
InfluentialSelf-citation
Flagged first, then by citations
1 of the 73 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 738
O'Malley, D. E., Raspin, K., Melton, P. E., Burdon, K. P., Dickinson, J. L., & FitzGerald, L. M. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02485-7 · Cited by 11
Saha, D., Dang, H. X., Zhang, M., Quigley, D. A., Feng, F. Y.-C., & Maher, C. A. (2024) · npj Genomic Medicine · doi:10.1038/s41525-024-00401-3 · Cited by 10
Self-citationFanelli, G. N., Nuzzo, P. V., Pederzoli, F., & Loda, M. F. (2024) · Surgical pathology clinics · doi:10.1016/j.path.2024.10.003 · Cited by 12
Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Chiu, C.-L., Zhang, D., Zhao, H., Wei, Y., Polasko, A. L., Thomsen, M. T., Yang, V., Yang, K., Hauck, J. S., Peterson, E. E., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3028 · Cited by 10
Self-citationAlrouji, M., Alshammari, M. S., Anwar, S., Venkatesan, K., & Shamsi, A. (2025) · Cancers · doi:10.3390/cancers17091554 · Cited by 10
Sun, R., Peng, J. C., Wang, Z., Yan, B., Zhu, S., Huang, Z., Zhang, J., Ding, D., Li, X., Wang, L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413732122 · Cited by 11
Self-citationNew frontiers in prostate cancer treatment from systemic therapy to targeted therapy
Nouruzi, S., Kobelev, M., Tabrizian, N., Gleave, M. E., & Zoubeidi, A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00282-8 · Cited by 13
Self-citationLin, X., Wang, Z., Wu, X., Zeng, T., Luo, W., Hu, X., Ni, Y., Che, G., Liu, L., Zhang, W., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109660 · Cited by 10
PGG.SV: a whole-genome-sequencing-based structural variant resource and data analysis platform
Wang, Y., Ling, Y., Gong, J., Zhao, X., Zhou, H., Xie, B., Lou, H., Zhuang, X., Li, J., Initiative, T. H., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac905 · Cited by 10
Pan, J. G., Zhao, J., Ni, X., Zhu, B., Hu, X., Wang, Q., Yu, W., Zhang, T., Gan, H., Wang, B., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06123-5 · Cited by 11
Exploiting the DNA Damage Response for Prostate Cancer Therapy
Stracker, T. H., Osagie, O. I., Escorcia, F. E., & Citrin, D. E. (2023) · Cancers · doi:10.3390/cancers16010083 · Cited by 12
Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex
Miranti, C. K., Moore, S., Kim, Y., Chappeta, V. R., Wu, K., De, B., Gokhale, V. M., Hurley, L. H., & Reyes‐Reyes, E. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27589 · Cited by 11
Jardim, D. L. F., Millis, S. Z., Ross, J. S., Woo, M. S.-A., Ali, S. M., & Kurzrock, R. (2021) · The Oncologist · doi:10.1002/onco.13694 · Cited by 10
Engineering chromosome rearrangements in cancer
Alonso, S., & Dow, L. E. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049078 · Cited by 11
Analysis of CDK12 alterations in a pan‐cancer database
Pan, E., Cabal, A., Javier-DesLoges, J. F., Patel, D. N., Panian, J. A., Lee, S., Shaya, J. A., Nonato, T. K., Xu, X., Stewart, T. F., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4483 · Cited by 10
Reference bias in the Illumina Isaac aligner
Cornish, A. J., Chubb, D., Frangou, A., Hoang, P. H., Kaiser, M., Wedge, D. C., & Houlston, R. S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa514 · Cited by 10
Huang, J., Du, M., Soupir, A. C., Wang, L., Tan, W. W., Kalari, K. R., Kilari, D., Park, J. Y., Huang, C., Kohli, M., et al. (2022) · Cancers · doi:10.3390/cancers14194714 · Cited by 9
Self-citationYu, W., Zhang, T., Wang, B., Pan, J. G., Jin, S., Fang, B., Gu, W., Qin, X., Dai, B., Lin, G., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13511 · Cited by 9
Logotheti, S., Papadaki, E., Zolota, V., Logothetis, C. J., Vrahatis, A. G., Soundararajan, R., & Tzelepi, V. (2023) · Cancers · doi:10.3390/cancers15174357 · Cited by 9
Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer
Martin‐Caraballo, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084171 · Cited by 9
Torasawa, M., Shukuya, T., Uemura, K., Hayashi, T., Ueno, T., Kohsaka, S., Masui, Y., Shirai, Y., Okura, M. K., Asao, T., et al. (2024) · Respirology · doi:10.1111/resp.14724 · Cited by 9
Chen, F., Zhang, Y., Shen, L., & Creighton, C. J. (2024) · Nature Communications · doi:10.1038/s41467-024-51276-y · Cited by 9
Zhao, Y., Ramesh, N., Xu, P. A., Sei, E., Hu, M., Bai, S., Troncoso, P., Aparicio, A. M., Logothetis, C. J., Corn, P. G., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-1943 · Cited by 9
Zhang, T., Wang, B., Yu, W., Gan, H., Fang, B., Li, X., Wu, J., Bian, X., Wang, J., Freedland, S. J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102018 · Cited by 9
Targeting radioresistance and replication fork stability in prostate cancer
Li, X., Baek, G., Carreira, S., Yuan, W., Ma, S., Hofstad, M. E., Lee, S., Gao, Y., Bertan, C. M., de la Maza, M. D. F., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.152955 · Cited by 10
Monaghan, A. E., Porter, A., Hunter, I., Morrison, A. J., McElroy, S. P., & McEwan, I. J. (2022) · Assay and Drug Development Technologies · doi:10.1089/adt.2021.128 · Cited by 9
Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
Cussenot, O., Cancel‐Tassin, G., Rao, S. R., Woodcock, D. J., Lamb, A. D. G., Mills, I. G., & Hamdy, F. C. (2023) · British Journal of Urology · doi:10.1111/bju.16120 · Cited by 10
Hauck, J. S., Moon, D., Jiang, X., Wang, M., Zhao, Y., Xu, L., Quang, H., Butler, W., Chen, M., Macias, E., et al. (2024) · Communications Biology · doi:10.1038/s42003-023-05727-9 · Cited by 10
Self-citationBergom, H. E., Sena, L. A., Day, A., Miller, B., Miller, C. D., Lozada, J. R., Zorko, N. A., Wang, J., Shenderov, E., Lobo, F. P., et al. (2024) · npj Genomic Medicine · doi:10.1038/s41525-024-00392-1 · Cited by 9
Biologie des métastases et mécanismes moléculaires de leur formation
Coussy, F., Bonin, F., Azorin, P., Tariq, Z., & Driouch, K. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.11.010 · Cited by 12
Montgomery, B. (2020) · Federal Practitioner · doi:10.12788/fp.0021 · Cited by 9
Smits, M., Ekici, K., Naga, S. P., van Oort, I. M., Sedelaar, J. P. M., Schalken, J. A., Nagarajah, J., Scheenen, T. W. J., Gerritsen, W. R., Fütterer, J. J., et al. (2020) · Cancers · doi:10.3390/cancers12123756 · Cited by 9
dos Santos, N. J., Camargo, A. C. L., Carvalho, H. F., Justulin, L. A., & Felisbino, S. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169224 · Cited by 9
ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems
Bergom, H. E., Shabaneh, A., Day, A., Ali, A. A.-M., Boytim, E., Tape, S., Lozada, J. R., Shi, X., Kerkvliet, C. J. P., McSweeney, S. T., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04795-1 · Cited by 9
Self-citationHe, Y., Johnson, D. T., Yang, J., Wu, H., You, S., Yoon, J., Lee, D., Kim, W. K., Aldahl, J., Le, V. L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0901-8 · Cited by 9
Self-citationZhao, F., Zeng, J., Chen, C., Zhao, X., Zhang, T., THOMAS, G. V., Sears, R. C., Alumkal, J. J., Moran, A. E., Mills, G. B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.18.629070 · Cited by 12
Self-citationMitsui, Y., Yamabe, F., Hori, S., Uetani, M., Aoki, H., Sakurabayashi, K., Okawa, M., Kobayashi, H., Nagao, K., & Nakajima, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-42711-z · Cited by 8
Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis
Bao, Y., Sui, X., Wang, X., Qu, N., Xie, Y., Cong, Y., & Cao, X. (2024) · International Journal of Cancer · doi:10.1002/ijc.34985 · Cited by 8
Shen, J., Lu, L., Chen, Z., Guo, W., Wang, S., Liu, Z., Gong, X., Qi, Y., Jin, R., & Zhang, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-96683-3 · Cited by 8
Beltran, H., Calais, J., Emmett, L., Kuo, P. H., & Logothetis, C. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1583168 · Cited by 8
Targeting Genome Stability in Melanoma—A New Approach to an Old Field
Osrodek, M., & Woźniak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073485 · Cited by 11
Whitlock, N. C., White, M. E., Capaldo, B. J., Ku, A. T., Agarwal, S., Fang, L., Wilkinson, S. C., Trostel, S. Y., Shi, Z.-D., Basuli, F., et al. (2022) · Discover Oncology · doi:10.1007/s12672-022-00565-3 · Cited by 8
Single-cell analysis revealing the metabolic landscape of prostate cancer
Wang, J., Ding, H.-K., Xu, H., Hu, D.-K., Hankey, W., Chen, L., Xiao, J., Liang, C.-Z., Zhao, B. Q., & Xu, L. (2024) · Asian Journal of Andrology · doi:10.4103/aja20243 · Cited by 9
A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations
Bogdanova, N. V., Schürmann, P., Valova, Y. V., Dubrowinskaja, N., Turmanov, N., Yugay, T., Essimsiitova, Z., Mingazheva, E., Prokofyeva, D. S., Bermisheva, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00493 · Cited by 8
Kang, M., Cho, E., Jang, J., Lee, J., Jeon, Y. J., Jeong, B. C., Seo, S. I., Jeon, S. S., Lee, H. M., Choi, H. Y., et al. (2019) · Korean journal of urology · doi:10.4111/icu.2019.60.4.227 · Cited by 8
Algorithmic approaches to clonal reconstruction in heterogeneous cell populations
Ismail, W. M., Nzabarushimana, É., & Tang, H. (2019) · Quantitative Biology · doi:10.1007/s40484-019-0188-3 · Cited by 8
Pham, M., Gupta, A., Gupta, H., Vaghasia, A. M., Skaist, A., Garrison, M. A., Coulter, J. B., Haffner, M. C., Zheng, S. L., Xu, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0683 · Cited by 8
Uusi-Mäkelä, J., Afyounian, E., Tabaro, F., Häkkinen, T., Lussana, A., Shcherban, A., Annala, M., Nurminen, R., Kivinummi, K. K., Tammela, T. L. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.08.287268 · Cited by 11
“Recurrent genomic alterations in primary and metastatic PC have been identified and their role in disease progression has been studied extensively (Armenia et al., 2018; Espiritu et al., 2018; Grasso et al., 2012; Gundem et al., 2015; Peng et al., 2015; Quigley et al., 2018; Robinson et al., 2015).”
NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancerPreprint
Li, J. J., Vasciaveo, A., Karagiannis, D., Sun, Z., Chen, X., Socciarelli, F., Frankenstein, Z., Zou, M., Pannellini, T., Chen, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.18.549585 · Cited by 9
Mechanistic insights into steroid hormone-mediated regulation of the androgen receptor gene
Gillen, A. D., Hunter, I., Ullner, E., & McEwan, I. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304183 · Cited by 7
Racial variation in the advanced prostate cancer genome
Feng, E., Vo-Phamhi, J. M., Subramanian, A., Dias, M., Foye, A., Vinson, J., Hong, J. C., Freedland, S. J., Alumkal, J. J., Beltran, H., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-025-00949-w · Cited by 7
Self-citationCAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives
Calabrò, M. L., Ettari, R., Chio, C. D., Luca, F. D., Previti, S., & Zappalà, M. (2025) · Biomedicines · doi:10.3390/biomedicines13102545 · Cited by 8
Ding, H.-K., Meng, Q., Zhou, J. M., Chen, L., Huang, J., Zhao, B. Q., & Xu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003844 · Cited by 7
Self-citationEmmenis, L. V., Ku, S., Gayvert, K. M., Branch, J. R., Brady, N. J., Basu, S., Russell, M. R., Cyrta, J., Vosoughi, A., Sailer, V. W., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0491 · Cited by 9
Chen, F., Zhang, Y., Sedlazeck, F. J., & Creighton, C. J. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101446 · Cited by 7
Weiss, S., Lamy, P., Rusan, M., Nørgaard, M., Ulhøi, B. P., Knudsen, M., Kassentoft, C. G., Farajzadeh, L., Jensen, J. B., Pedersen, J. S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34949 · Cited by 9
Fracassi, G., Lorenzin, F., Orlando, F., Gioia, U., D’Amato, G., Casaramona, A. S., Cantore, T., Prandi, D., Santer, F. R., Klocker, H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179393 · Cited by 11
Bizzaro, C. L., Bach, C. A., Santos, R. A., Verrillo, C. E., Naranjo, N. M., Chaudhari, I., Picone, F. J., Iqbal, W., Blidner, A. G., Rabinovich, G. A., et al. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0903 · Cited by 7
Sequence of events in prostate cancer
Cotter, K. A., & Rubin, M. A. (2018) · Nature · doi:10.1038/d41586-018-06029-5 · Cited by 7
Laera, L., Guaragnella, N., Giannattasio, S., & Moro, L. (2019) · Cancers · doi:10.3390/cancers11070945 · Cited by 8
Branch, J. R., Bush, T. L., Pande, V., Connolly, P. J., Zhang, Z., Hickson, I., Ondrus, J., Jaensch, S., Bischoff, J. R., Habineza, G., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0510 · Cited by 7
Zhang, Z., Connolly, P. J., Escolar, L. T., Rocaboy, C., Pande, V., Meerpoel, L., Lim, H., Branch, J. R., Ondrus, J., Hickson, I., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00032 · Cited by 7
Mako: A Graph-Based Pattern Growth Approach to Detect Complex Structural Variants
Lin, J., Yang, X., Kosters, W. A., Xu, T., Jia, Y., Wang, S., Zhu, Q., Ryan, M., Guo, L., Gerstein, M., et al. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2021.03.007 · Cited by 7
Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types
Elliott, A., Zhang, J., Zhang, Q. H., Swensen, J. J., Martin, D., Xiu, J., Geynisman, D. M., Vaena, D. A., Herzog, T. J., Holloway, R. W., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.08.010 · Cited by 8
Self-citationStover, E. H., Oh, C., Keskula, P., Choudhury, A. D., Tseng, Y., Adalsteinsson, V. A., Lohr, J. G., Thorner, A. R., Ducar, M. D., Kryukov, G. V., et al. (2022) · The Prostate · doi:10.1002/pros.24305 · Cited by 7
Nanomedicine for the Treatment of Advanced Prostate Cancer
Vicente‐Ruiz, S., Serrano‐Martí, A., Armiñán, A., & Vicent, M. J. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000136 · Cited by 7
Park, S., Lee, H.-Y., Park, H., Ju, Y. S., Kim, J., Kim, E., & Kim, J. (2021) · Cancers · doi:10.3390/cancers13051125 · Cited by 7
Lercher, L., Simon, N., Bergmann, A., Tauchert, M. J., Bochmann, D., Bashir, T., Neuefeind, T., Riley, D., Danna, B., Krawczuk, P. J., et al. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.04.003 · Cited by 7
Brown, J. B., Sriram, R., Criekinge, M. V., Santos, R. D., Sun, J., Santos, J. D., Tabatabai, Z. L., Shinohara, K., Nguyen, H. G., Peehl, D. M., et al. (2019) · Magnetic Resonance in Medicine · doi:10.1002/mrm.27739 · Cited by 7
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
Chrenková, E., Študentová, H., Holá, K., Kahounová, Z., Hendrychová, R., Souček, K., & Bouchal, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394292 · Cited by 6
Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution
Furlano, K., Keshavarzian, T., Biernath, N., Fendler, A., Santis, M. D., Weischenfeldt, J., & Lupien, M. (2025) · International Journal of Cancer · doi:10.1002/ijc.35327 · Cited by 6
Shuai, Y., & Huang, H. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.06.001 · Cited by 6
“97 , 98 101 The MYC signaling pathway plays a critical oncogenic role in prostate cancer, influencing tumor cell growth, metastasis, and therapy response.”
Halabi, S., Guo, S., Luo, B., Yu, C., Knutson, T. P., Kobilka, A., Lyman, J., Beltran, H., Antonarakis, E. S., Galsky, M. D., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.07.011 · Cited by 9
Self-citationBergström, S. H., Semenas, J., Nordstrand, A., Thysell, E., Wänman, J., Crnalic, S., Widmark, A., Karlsson, C. T., Andersson, P. H., Gidlund, S., et al. (2025) · Clinical & Experimental Metastasis · doi:10.1007/s10585-025-10365-y · Cited by 6
Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer
Ahmad, F., White, M. E., Yamamoto, K., Crooks, D. R., Agarwal, S., Yang, Y., Capaldo, B. J., Raj, S., Alilin, A. N., Ton, A., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101235 · Cited by 6
Koo, K. M., Phillips, G., Srihari, S., Farrell, Á., Jaradi, B., Fitzpatrick, K. J., Yaxley, J. W., Samaratunga, H., Mainwaring, P. N., Ru, K., et al. (2026) · Advanced Science · doi:10.1002/advs.202512126 · Cited by 6
Self-citationKneppers, J., Bergman, A. M., & Zwart, W. T. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_15 · Cited by 6
Future therapeutic strategies for metastatic prostate cancer
Smits, M., Gerritsen, W. R., & Mehra, N. (2019) · Tijdschrift voor Urologie · doi:10.1007/s13629-019-00261-y · Cited by 6
Levine, R. D. (2020) · Federal Practitioner · doi:10.12788/fp.0035 · Cited by 6
Eteleeb, A. M., Quigley, D. A., Zhao, S. G., Pham, D., Yang, R., Dehm, S. M., Luo, J. R., Feng, F. Y.-C., Dang, H. X., & Maher, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-71168-7 · Cited by 6
Self-citationTumor size and genomic risk in localized prostate cancer
Gaffney, C., Liu, D., Cooley, V., Ma, X., Angulo, C., Robinson, B. D., Khani, F., Cai, P. Y., Salami, S. S., Nallandhighal, S., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.01.020 · Cited by 6
Su, Q., Dai, B., Zhang, H., & Zhang, S. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/8430485 · Cited by 6
RetractedMartinez‐Fundichely, A., Dixon, A., & Khurana, E. (2022) · Nature Communications · doi:10.1038/s41467-022-32945-2 · Cited by 5
Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling
Nikesitch, N., Beraldi, E., Zhang, F., Adomat, H. H., Bell, R. H., Suzuki, K., Fazli, L., Kung, S. H. Y., Wells, C. A., Pinette, N. C., et al. (2023) · Oncogene · doi:10.1038/s41388-022-02573-7 · Cited by 6
Self-citationLi, G., Pu, P., Pan, M., Weng, X., Qiu, S., Li, Y., Abbas, S. J., Zou, L., Liu, K., Wang, Z., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1008-8 · Cited by 6
Precision medicine for prostate cancer: An international perspective
Hamid, A., Sweeney, C. J., Hovens, C. M., Corcoran, N. M., & Azad, A. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.02.004 · Cited by 9
ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men
Jiang, B., Sedarsky, J., Srivastava, S. K., Sesterhenn, I. A., Dobi, A. L., & Li, Q. (2019) · Journal of Cancer · doi:10.7150/jca.30025 · Cited by 7
Circulating cell-free DNA: Translating prostate cancer genomics into clinical care
Tandefelt, D. G., & Bono, J. S. D. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100837 · Cited by 6
Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer
Carneiro, B. A., Lotan, T. L., Souza, A. O., & Aggarwal, R. R. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100025 · Cited by 6
Self-citationProstate Cancer Progression and the Epigenome
Arap, W., Pasqualini, R., & Costello, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmcibr2030475 · Cited by 6
Assessing the contribution of tumor mutational phenotypes to cancer progression risk
Tao, Y., Rajaraman, A., Cui, X., Cui, Z., Chen, H., Zhao, Y., Eaton, J., Kim, H., Ma, J., & Schwartz, R. S. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008777 · Cited by 6
Peinetti, N., Bilušić, M., & Burnstein, K. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci165357 · Cited by 6
The promise of immunotherapy in genitourinary malignancies
Zhang, T., Armstrong, A. J., George, D. J., & Huang, J. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby018 · Cited by 6
Self-citationPARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers
Mateo, J., Carreira, S., & Bono, J. S. D. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.029 · Cited by 6
Androgen blockade primes NLRP3 in macrophages to induce tumor phagocytosisPreprint
Chaudagar, K. K., Rameshbabu, S., Mei, S., Hirz, T., Hu, Y., Argulian, A., Labadie, B. W., Desai, K. B., Grimaldo, S., Kahramangil, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557996 · Cited by 6
Systems-level liquid biopsy in advanced prostate cancer
Lyman, J. A., & Dehm, S. M. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0274 · Cited by 5
Self-citationAmsberg, G. V., Dyshlovoy, S. A., & Kaune, M. (2025) · Die Urologie · doi:10.1007/s00120-024-02511-3 · Cited by 5
Zakari, S., Rotimi, S. O., Bholah, C. T., & Ogunlana, O. O. (2025) · Scientifica · doi:10.1155/sci5/4084224 · Cited by 5
Ying, Y., Liu, Q., Li, X., Zhang, H., Xu, X., Ma, Q., Nowsheen, S., Aziz, K., Li, Y., Lou, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw7989 · Cited by 6
Ersoy-Fazlioglu, B., Lingadahalli, S., Altıntaş, U. B., Cingöz, A., Tekoglu, E., Yu, I. P. L., Dikbas, U. M., Missaghimamaghani, O., Yavuz, K., Adomat, H. H., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500327122 · Cited by 8
“Looking at publicly available RNA - seq of an independent CRPC cohort (24), we found that HOXB13 mRNA expression was reduced but still expressed in many AR - negative tumors (Fig.”
Self-citation
Metadata
- Authors
- Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. M., Thomas, G., Chi, K. N., Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J., & Feng, F. Y.
- Affiliations
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- Oregon Health & Science University (US)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- University of California, Los Angeles (US)
- University of Minnesota (US)
- University of California Davis Medical Center (US)
- University of California, Santa Cruz (US)
- Illumina (United States) (US)
- Thomas Jefferson University (US)
- University Health Network (CA)
- Duke University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- ORCID
- Quigley, David A.
- Dang, Ha X.
- Zhao, Shuang G.
- Lloyd, Paul
- Aggarwal, Rahul
- Alumkal, Joshi J.
- Foye, Adam
- Kothari, Vishal
- Perry, Marc D.
- Zhang, Li
- Zhang, Jin
- Youngren, Jack F.
- Cieslik, Marcin P.
- Parolia, Abhijit
- Beer, Tomasz M.
- Thomas, George
- Chi, Kim N.
- Gleave, Martin
- Lack, Nathan A.
- Zoubeidi, Amina
- Reiter, Robert E.
- Rettig, Matthew B.
- Witte, Owen
- Ryan, Charles J.
- Fong, Lawrence
- Kim, Won
- Friedlander, Terence
- Chou, Jonathan
- Li, Haolong
- Das, Rajdeep
- Li, Hui
- Goodarzi, Hani
- Gilbert, Luke A.
- Lara, Primo N.
- Evans, Christopher P.
- Goldstein, Theodore C.
- Stuart, Joshua M.
- Tomlins, Scott A.
- Spratt, Daniel E.
- Farh, Kyle
- Gehring, Julian S.
- Hakenberg, Jörg
- Shon, John
- Sickler, Brad
- Batzoglou, Serafim
- Knudsen, Karen E.
- He, Housheng H.
- Huang, Jiaoti
- Wyatt, Alexander W.
- Dehm, Scott M.
- Ashworth, Alan
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 174
- Issue
- 3
- Pages
- 758-769.e9
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6425931
- OpenAlex
- W2884001931
- Semantic Scholar
- c72ffe522bd85597687b47e4d3db90ec72b4fc80
- Cited by
- 733
- References
- 73
- Citations by year
- 2026: 48 · 2025: 73 · 2024: 102 · 2023: 107 · 2022: 94 · 2021: 110 · 2020: 102 · 2019: 81 · 2018: 15
- FWCI
- 58.02
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-18)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Stand Up To Cancer-Prostate Cancer Foundation Prostate Cancer Dream Team Award (SU2C-AACR-DT0812, SU2C-AACR-DT0712)
- Movember Foundation
- Goldberg-Benioff Research Fund for Prostate Cancer Translational Biology
- Prostate Cancer Foundation Challenge
- V Foundation
- BRCA Foundation Young Investigator Award
- Department of Defense (W81XWH-16-1-0747, W81XWH-15-1-0562, PC160429, W81XWH-17-1-0192)
- Early Detection Research Network (U01 CA214170)
- Prostate SPORE (P50 CA186786, P50 CA097186)
- NIH (R01CA174777)
- NCI T32 (CA108462)
- Prostate Cancer Foundation Young Investigator Awards
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, structural variants, androgen receptor, c-Myc, tandem duplication, long non-coding RNA, DNA repair deficiency, CDK12, TP53, chromothripsis, BRCA2
- MeSH terms
- Whole Genome Sequencing, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-myc, Cyclin-Dependent Kinases, Tandem Repeat Sequences, Gene Expression Profiling, Genomics, BRCA2 Protein, Genomic Structural Variation, DNA Copy Number Variations, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
